Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
by Zacks Equity Research
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
NERVNegative Net Change ESPRNegative Net Change MRNSPositive Net Change KRYSNegative Net Change
medical
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
by Zacks Equity Research
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
PFENegative Net Change HRTXNegative Net Change MRNSPositive Net Change ARQTNegative Net Change
biotechs medical pharmaceuticals vaccines
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
by Sundeep Ganoria
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change CVACNegative Net Change
biotechs medical pharmaceuticals vaccines
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
by Zacks Equity Research
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
KRYSNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
MDTNegative Net Change RMDNegative Net Change MEDPPositive Net Change EHCNegative Net Change
earnings medical medical-devices
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by strategic alliances and new product launches.
RMDNegative Net Change WBANegative Net Change MEDPPositive Net Change EHCNegative Net Change
medical medical-devices
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
BSXNegative Net Change RMDNegative Net Change MEDPPositive Net Change HIMSPositive Net Change
medical
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
by Zacks Equity Research
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
RMDNegative Net Change VCYTPositive Net Change MEDPPositive Net Change HIMSPositive Net Change
medical
Globus Medical (GMED) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.
RMDNegative Net Change GMEDNegative Net Change MEDPPositive Net Change HIMSPositive Net Change
medical medical-devices
Do Options Traders Know Something About Alcon (ALC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
ALCNegative Net Change
medical
Intuitive Surgical (ISRG) Hits 52-Week High on Procedure Demand
by Zacks Equity Research
Intuitive Surgical's (ISRG) da Vinci procedure volume, coupled with strong Ion procedure growth, is fueling the rally in the company???s share price.
ISRGNegative Net Change DVAPositive Net Change ALGNNegative Net Change MEDPPositive Net Change
medical medical-devices
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
BSXNegative Net Change ECLNegative Net Change DVAPositive Net Change NARIPositive Net Change
medical medical-devices
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
by Zacks Equity Research
Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs immuno-therapy medical pharmaceuticals
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
BMYNegative Net Change LGNDNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
CVS Health (CVS) Expands Food and Beverage Line With New Launch
by Zacks Equity Research
CVS Health's (CVS) Well Market brand offers a blend of mouthwatering flavors and nutritious options, expertly crafted and taste-tested by food enthusiasts.
RMDNegative Net Change CVSNegative Net Change MEDPPositive Net Change EHCNegative Net Change
medical medical-devices
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
BSXNegative Net Change ECLNegative Net Change DVAPositive Net Change MMSINegative Net Change
medical medical-devices
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest offering is likely to create an efficient approach to inflation, thereby providing improved patient care.
BSXNegative Net Change ECLNegative Net Change DVAPositive Net Change MMSINegative Net Change
medical medical-devices
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
by Zacks Equity Research
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
BSXNegative Net Change ECLNegative Net Change ANGOPositive Net Change ALGNNegative Net Change
medical medical-devices
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
RDYPositive Net Change ANVSNegative Net Change ALXONegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
Encompass Health (EHC) Opens Rehabilitation Hospital in Ballwin
by Zacks Equity Research
The 40-bed inpatient rehabilitation hospital is a JV between Encompass Health (EHC) and BJC HealthCare.
BKDNegative Net Change HQYNegative Net Change EHCNegative Net Change SERANegative Net Change
medical
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
by Zacks Equity Research
The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.
BIIBPositive Net Change MRNSPositive Net Change ENTXNegative Net Change LRMRPositive Net Change
medical
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
BSXNegative Net Change ECLNegative Net Change DVAPositive Net Change HQYNegative Net Change
medical medical-devices
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
by Zacks Equity Research
Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
RMDNegative Net Change BRKRNegative Net Change MEDPPositive Net Change HIMSPositive Net Change
medical
Zacks Initiates Coverage of FitLife Brands With Neutral Recommendation
by Debanjana Dey
Find out why Zacks rates FitLife Brands as "Neutral," being the first on Wall Street to initiate coverage on the stock. Explore FTLF's strategic growth and financial health amid market challenges.
FTLFPositive Net Change
medical
Here's Why You Should Buy Haemonetics (HAE) Stock Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
RMDNegative Net Change HAEPositive Net Change MEDPPositive Net Change HIMSPositive Net Change
medical medical-devices